Log in

Gilead Sciences News Headlines (NASDAQ:GILD)

$63.81
+0.48 (+0.76 %)
(As of 11/15/2019 05:03 AM ET)
Today's Range
$62.38
Now: $63.81
$64.00
50-Day Range
$61.65
MA: $64.01
$66.48
52-Week Range
$60.32
Now: $63.81
$72.90
Volume7.55 million shs
Average Volume6.61 million shs
Market Capitalization$80.73 billion
P/E Ratio10.38
Dividend Yield3.98%
Beta1.09

Headlines

Gilead Sciences (NASDAQ GILD) News Headlines

Source:
DateHeadline
Notable Thursday Option Activity: GILD, GEO, TTWONotable Thursday Option Activity: GILD, GEO, TTWO
www.nasdaq.com - November 14 at 3:58 PM
Gilead Sciences (GILD) Shares Cross 4% Yield MarkGilead Sciences (GILD) Shares Cross 4% Yield Mark
www.nasdaq.com - November 14 at 3:58 PM
Zacks: Analysts Anticipate Gilead Sciences, Inc. (NASDAQ:GILD) Will Announce Quarterly Sales of $5.74 BillionZacks: Analysts Anticipate Gilead Sciences, Inc. (NASDAQ:GILD) Will Announce Quarterly Sales of $5.74 Billion
www.americanbankingnews.com - November 14 at 4:25 AM
$1.70 Earnings Per Share Expected for Gilead Sciences, Inc. (NASDAQ:GILD) This Quarter$1.70 Earnings Per Share Expected for Gilead Sciences, Inc. (NASDAQ:GILD) This Quarter
www.americanbankingnews.com - November 12 at 8:02 PM
Gilead Sciences (NASDAQ:GILD) Receives New Coverage from Analysts at SunTrust BanksGilead Sciences (NASDAQ:GILD) Receives New Coverage from Analysts at SunTrust Banks
www.americanbankingnews.com - November 12 at 9:07 AM
Will Its HIV Lineup Save Gilead Sciences?Will Its HIV Lineup Save Gilead Sciences?
www.nasdaq.com - November 11 at 1:18 PM
Did You Invest in Gilead Sciences?Did You Invest in Gilead Sciences?
finance.yahoo.com - November 8 at 9:20 PM
Gilead Announces New Data from Viral Hepatitis Research Programs at The Liver Meeting® 2019Gilead Announces New Data from Viral Hepatitis Research Programs at The Liver Meeting® 2019
finance.yahoo.com - November 8 at 4:19 PM
Gilead Presents Data on Investigational HIV-1 Capsid Inhibitor GS-6207 as a Potential Component of Long-Acting HIV TherapyGilead Presents Data on Investigational HIV-1 Capsid Inhibitor GS-6207 as a Potential Component of Long-Acting HIV Therapy
finance.yahoo.com - November 8 at 4:19 PM
Data Showing Potential for Machine Learning to Advance Understanding of Nonalcoholic Steatohepatitis (NASH) Presented at the Liver Meeting® 2019Data Showing Potential for Machine Learning to Advance Understanding of Nonalcoholic Steatohepatitis (NASH) Presented at the Liver Meeting® 2019
finance.yahoo.com - November 8 at 4:19 PM
Is The Future Finally Looking Up For Gilead Sciences?Is The Future Finally Looking Up For Gilead Sciences?
www.fool.com - November 8 at 7:52 AM
Brett A. Pletcher Sells 2,095 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) StockBrett A. Pletcher Sells 2,095 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) Stock
www.americanbankingnews.com - November 7 at 10:44 PM
Trump administration sues Gilead Sciences over HIV prevention patentsTrump administration sues Gilead Sciences over HIV prevention patents
www.marketwatch.com - November 7 at 4:43 PM
US sues Gilead over HIV patent infringementsUS sues Gilead over HIV patent infringements
finance.yahoo.com - November 7 at 4:43 PM
Trump administration sues Gilead Sciences   over HIV prevention patentsTrump administration sues Gilead Sciences over HIV prevention patents
finance.yahoo.com - November 7 at 4:43 PM
Gilead Sciences, Inc. (NASDAQ:GILD) Receives Average Recommendation of "Buy" from AnalystsGilead Sciences, Inc. (NASDAQ:GILD) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 7 at 10:51 AM
Galapagos increases share capital through warrant exercise by GileadGalapagos increases share capital through warrant exercise by Gilead
www.marketwatch.com - November 6 at 5:30 PM
Gilead HIV meds show sustained benefit in late-stage studiesGilead HIV meds show sustained benefit in late-stage studies
seekingalpha.com - November 6 at 12:29 PM
Kite to Present New Data From Industry-leading Cell Therapy Portfolio at ASH 2019Kite to Present New Data From Industry-leading Cell Therapy Portfolio at ASH 2019
finance.yahoo.com - November 6 at 12:29 PM
Gilead Presents 96-week Discover Trial Data...Gilead Presents 96-week Discover Trial Data...
www.benzinga.com - November 6 at 7:29 AM
Gilead’s Biktarvy Maintained High Efficacy With No Cases of Treatment-Emergent Resistance Through Three Years in Phase 3 HIV Clinical TrialsGilead’s Biktarvy Maintained High Efficacy With No Cases of Treatment-Emergent Resistance Through Three Years in Phase 3 HIV Clinical Trials
finance.yahoo.com - November 6 at 7:29 AM
Gilead Presents 96-week Discover Trial Data Supporting Non-inferior Efficacy and Key Safety Differences of Descovy For PrEP™ Compared With Truvada For PrEP®Gilead Presents 96-week Discover Trial Data Supporting Non-inferior Efficacy and Key Safety Differences of Descovy For PrEP™ Compared With Truvada For PrEP®
finance.yahoo.com - November 6 at 7:29 AM
Gilead Sciences, Inc. (NASDAQ:GILD) EVP Sells $258,080.00 in StockGilead Sciences, Inc. (NASDAQ:GILD) EVP Sells $258,080.00 in Stock
www.americanbankingnews.com - November 5 at 8:52 PM
This Insider Has Just Sold Shares In Gilead Sciences, Inc. (NASDAQ:GILD)This Insider Has Just Sold Shares In Gilead Sciences, Inc. (NASDAQ:GILD)
finance.yahoo.com - November 2 at 2:06 PM
Gilead delivers exercise notice to Galapagos for Initial Warrant A to increase ownership to 25.1%Gilead delivers exercise notice to Galapagos for Initial Warrant A to increase ownership to 25.1%
www.marketwatch.com - November 1 at 11:15 PM
Gilead to up stake in Galapagos to 25.1%Gilead to up stake in Galapagos to 25.1%
seekingalpha.com - November 1 at 11:15 PM
Gilead and Galapagos to Present New Data on Filgotinib at 2019 ACR/ARP Annual MeetingGilead and Galapagos to Present New Data on Filgotinib at 2019 ACR/ARP Annual Meeting
finance.yahoo.com - October 31 at 6:59 PM
Gilead Sciences, Inc. (NASDAQ:GILD) EVP Brett A. Pletcher Sells 5,677 SharesGilead Sciences, Inc. (NASDAQ:GILD) EVP Brett A. Pletcher Sells 5,677 Shares
www.americanbankingnews.com - October 30 at 10:17 PM
Merck strikes out in bid to reverse adverse ruling in Hep C patent fight with GileadMerck strikes out in bid to reverse adverse ruling in Hep C patent fight with Gilead
seekingalpha.com - October 30 at 12:27 PM
UPDATE 1-Merck loses bid to revive $2.54 bln patent verdict against GileadUPDATE 1-Merck loses bid to revive $2.54 bln patent verdict against Gilead
finance.yahoo.com - October 30 at 12:27 PM
Biotech Stock Roundup: Q3 Earnings Beat at ALXN & AMGN, Pipeline Updates & MoreBiotech Stock Roundup: Q3 Earnings Beat at ALXN & AMGN, Pipeline Updates & More
finance.yahoo.com - October 30 at 12:27 PM
Galapagos Quarterly Results: Gilead Profit Recognition And Important Catalysts For 2020Galapagos' Quarterly Results: Gilead Profit Recognition And Important Catalysts For 2020
seekingalpha.com - October 30 at 12:37 AM
Can New Drugs Help Gilead Sciences Rebound?Can New Drugs Help Gilead Sciences Rebound?
www.fool.com - October 29 at 10:22 AM
Gilead Sciences (NASDAQ:GILD) Given a $76.00 Price Target by Robert W. Baird AnalystsGilead Sciences (NASDAQ:GILD) Given a $76.00 Price Target by Robert W. Baird Analysts
www.americanbankingnews.com - October 28 at 7:21 PM
Gilead Sciences (NASDAQ:GILD) Given a $75.00 Price Target by Morgan Stanley AnalystsGilead Sciences (NASDAQ:GILD) Given a $75.00 Price Target by Morgan Stanley Analysts
www.americanbankingnews.com - October 28 at 7:21 PM
Wells Fargo & Co Analysts Give Gilead Sciences (NASDAQ:GILD) a $81.00 Price TargetWells Fargo & Co Analysts Give Gilead Sciences (NASDAQ:GILD) a $81.00 Price Target
www.americanbankingnews.com - October 28 at 6:05 PM
Gilead Sciences (NASDAQ:GILD) PT Set at $86.00 by GuggenheimGilead Sciences (NASDAQ:GILD) PT Set at $86.00 by Guggenheim
www.americanbankingnews.com - October 28 at 4:45 PM
Gilead teams up with Glympse Bio in NASH programGilead teams up with Glympse Bio in NASH program
seekingalpha.com - October 28 at 12:30 PM
Dont Sell Gilead Sciences, Inc. (NASDAQ:GILD) Before You Read ThisDon't Sell Gilead Sciences, Inc. (NASDAQ:GILD) Before You Read This
finance.yahoo.com - October 28 at 12:30 PM
Gilead and Glympse Bio Announce Strategic Collaboration for Use of Biomarker Technology in NASH Clinical DevelopmentGilead and Glympse Bio Announce Strategic Collaboration for Use of Biomarker Technology in NASH Clinical Development
finance.yahoo.com - October 28 at 12:30 PM
Don't Sell Gilead Sciences, Inc. (NASDAQ:GILD) Before You Read ThisDon't Sell Gilead Sciences, Inc. (NASDAQ:GILD) Before You Read This
finance.yahoo.com - October 28 at 12:30 PM
Gilead Sciences: Soft, Yet Solid EnoughGilead Sciences: Soft, Yet Solid Enough
seekingalpha.com - October 27 at 11:50 PM
Analysts Are Getting Impatient With Gilead Despite Decent EarningsAnalysts Are Getting Impatient With Gilead Despite Decent Earnings
www.nasdaq.com - October 27 at 8:49 AM
BMO Capital Markets Lowers Gilead Sciences (NASDAQ:GILD) Price Target to $81.00BMO Capital Markets Lowers Gilead Sciences (NASDAQ:GILD) Price Target to $81.00
www.americanbankingnews.com - October 26 at 9:25 AM
Gilead Sciences (NASDAQ:GILD) Given New $81.00 Price Target at Raymond JamesGilead Sciences (NASDAQ:GILD) Given New $81.00 Price Target at Raymond James
www.americanbankingnews.com - October 26 at 9:25 AM
Gilead Falls On Uninspiring Q3 Print: 3 Analyst TakesGilead Falls On Uninspiring Q3 Print: 3 Analyst Takes
finance.yahoo.com - October 25 at 5:01 PM
Gilead Sciences Turnaround Is HereGilead Sciences' Turnaround Is Here
seekingalpha.com - October 25 at 5:01 PM
Gilead Sciences Q3 Revenue Is Flat, and R&D Hits EarningsGilead Sciences Q3 Revenue Is Flat, and R&D Hits Earnings
www.fool.com - October 25 at 3:14 PM
Gilead Sciences (NASDAQ:GILD) Given New $80.00 Price Target at OppenheimerGilead Sciences (NASDAQ:GILD) Given New $80.00 Price Target at Oppenheimer
www.americanbankingnews.com - October 25 at 2:41 PM
Gilead Sciences (NASDAQ:GILD) Receives Overweight Rating from Cantor FitzgeraldGilead Sciences (NASDAQ:GILD) Receives Overweight Rating from Cantor Fitzgerald
www.americanbankingnews.com - October 25 at 1:05 PM
This page was last updated on 11/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel